Rolapitant hydrochloride (anhydrous) is a hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of the hydrate) for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Among its listed roles, it functions as a antiemetic and a neurokinin-1 receptor antagonist. It includes a rolapitant. It is grouped under the following drug class(es): Antiemetics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Varubi and TS-08867. Its PubChem CID is 71587824.
Rolapitant hydrochloride
| CAS No | 858102-79-1 |
|---|---|
| Molecular Formula | C25H27ClF6N2O2 |
| Molecular Weight | 536.9 g/mol |
| Synonyms | (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rolapitant hydrochloride (anhydrous) is a hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of the hydrate) for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
The listed CAS number is 858102-79-1.
The listed molecular formula is C25H27ClF6N2O2.
The listed molecular weight is 536.9 g/mol.
(5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one;hydrochloride.
The source lists Varubi and TS-08867.